Aim To analyse the resolution of chest X-ray findings in relation to laboratory parameters in patients infected with acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a two- month followup. Analysis of chest X-ray findings in the first few months after the disease is the main goal of our work. Methods Out of the total of 343 patients chest X-ray findings were followed in 269 patients. Patients were divided into groups according to the severity of findings. D-dimer, inflammatory markers, blood cell count, neutrophil lymphocyte ratio (NLR) were analysed. Chest X-ray was analysed during the hospitalization on the day of admission, on the third, the seventh and the fourteenth day (scoring method was used). After discharge chest X-ray was performed in a two-week follow-up, then after one and two months, and after three months if necessary. Results Incomplete chest X-ray resolution was identified in 24 (39.34%) patients with severe, 27 (22.31 %) patients with moderate and in three (3.91%) patients with mild findings. Statistical significance was established in overall score by comparison between all groups (p<0.001), and in the moderate compared to the mild group (p=0.0051). The difference of NLR in the severe compared to the moderate group was observed (p=0.0021) and in the severe group compared to the mild group (p=0.00013). Conclusion Chest X-ray findings persisted mostly in the severe group followed by the moderate and mild ones. Long-term followup is necessary for the appropriate treatment and prevention of fibrosis, and reduction of symptoms.
Tong J, Wong A, Zhu D, Fastenberg J, Tham T. The Prevalence of olfactory and gustatory dysfunction in COVID-19 patients: A systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2020;3–11.
2.
Ackermann M, Verleden S, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;120–8.
3.
Lechien J, Chiesa-Estomba C, Place S, Van Laethem Y, Cabaraux P, Mat Q, et al. COVID-19 Task Force of YO-IFOS. Clinical and epidemiological characteristics of 1,420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med. 2020;335–44.
4.
Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020;2268–70.
5.
Batlle D, Soler M, Sparks M, Hiremath S, South A, Welling P, et al. Acute kidney injury in COVID-19: emerging evidence of a distinct pathophysiology. J Am Soc Nephrol. 2020;1380–3.
6.
Cummings M, Baldwin M, Abrams D, Jacobson S, Meyer B, Balough E, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;1763–70.
7.
Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;1421–4.
8.
Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis. 2020;55–8.
9.
Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Throm Haemost. 2020;844–7.
10.
Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt G, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003;1986–94.
11.
Martines R, Ritter J, Matkovic E, Gary J, Bollweg B, Bullock H, et al. CO-VID-19 Pathology working group. Pathology and pathogenesis of SARS-CoV-2 associated with fatal coronavirus disease, United States. Emerg Infect Dis. 2020;2005–15.
12.
Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan. Lancet Respir Med. 2020;475–81.
13.
Mo X, Jian W, Su Z, Chen M, Peng H, Peng P, et al. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur Respir J. 2020;2001–17.
14.
Zhu N, Zhang D, Li W, Yang X, Song B, Zhao J, et al. A novel coronavirus from patients with pneumonia in China. N Engl J Med. 2020;
15.
Yufei Y, Mingli L, Xuejiao L, Xuemei D, Yiming J, Qin Q, et al. Utility of the neutrophil-tolymphocyte ratio and C-reactive protein level for coronavirus disease 2019 (COVID-19). Scand J Clin Lab Invest. 2020;536–40.
16.
Pimentel G, Vega D, Laviano C, A. High neutrophil to lymphocyte ratio as a prognostic marker in COVID-19 patients. Clin Nutr ESPEN. 2020;101–2.
17.
Li X, Liu C, Mao Z, Minglu X, Li W, Shuang Q, et al. Predictive values of neutrophil-to-lymphocyte ratio on disease severity and mortality in COVID-19 patients: a systematic review and meta-analysis. Crit Care. 2020;647.
18.
Maroldi R, Rondi P, Agazzi G, Ravanelli M, Borghesi A, Farina D. Which role for chest x-ray score in predicting the outcome in COVID-19 pneumonia? Eur Radiol. 2021;4016–22.
19.
Rubin G, Ryerson C, Haramati L, Sverzellati N, Kanne J, Raoof S, et al. The role of chest imaging in patient management during the COVID-19 pandemic: a multinational consensus statement from the Fleischner Society. Chest. 2020;106–16.
20.
Monaco C, Zaottini F, Schiaffino S, Villa A, Pepa D, Carbonaro G, et al. Chest x-ray severity score in COVID-19 patients on emergency department admission: a two-centre study. Eur Radiol Exp. 2020;68.
21.
Chang Y, Yu C, Chang S, Galvin J, Liu H, Hsiao C, et al. Pulmonary sequelae in convalescent patients after severe acute respiratory syndrome: evaluation with thin-section CT. Radiology. 2005;1067–75.
22.
Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;1607–8.
23.
Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo F, Chong M, et al. Characteristics and outcomes of 21 critically Ill patients with COVID-19 in Washington State. JAMA. 2020;1612–4.
24.
Moore J, June C. Cytokine release syndrome in severe COVID-19. Science. 2020;473–4.
25.
Kurupatham L, Chen M, Chan M, Vasoo S, Wang L, Tan B, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA. 2020;1488–94.
26.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. Lancet. 2020;497–506.
27.
Ojo A, Balogun S, Williams O, Ojo O. Pulmonary fibrosis in COVID-19 survivors: predictive factors and risk reduction strategies. Pulm Med. 2020;6175964.
28.
Strieter R, Mehrad B. New mechanisms of pulmonary fibrosis. Chest. 2009;1364–70.
29.
Bustin S, Benes V, Garson J, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;611–22.
30.
Ye Z, Zhang Y, Wang Y, Huang Z, Song B. Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review. Eur Radiol. 2020;4381–9.
31.
Schiaffino S, Tritella S, Cozzi A, Carriero S, Blandi L, Ferraris L, et al. Diagnostic performance of chest X-ray for COVID-19 pneumonia during the SARS-CoV-2 pandemic in Lombardy. Italy J Thorac Imaging. 2020;105–6.
32.
Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time course of lung changes at chest CT during recovery from coronavirus disease 2019 (COVID-19). Radiology. 2020;715–21.
33.
Huang L, Han R, Ai T, Yu P, Kang H, Tao Q, et al. Serial quantitative chest CT assessment of CO-VID-19: Deep-Learning approach. Radiol Cardiothorac Imaging. 2020;
34.
Venkatesan P. NICE guideline on long COVID. Lancet. Respir Med. 2021;129.
35.
Taylor E, Haven K, Reed P, Bissielo A, Harvey D, Mcarthur C, et al. Grant CC; SHIVERS Investigation Team. A chest radiograph scoring system in patients with severe acute respiratory infection: a validation study. BMC Med Imaging. 2015;61.
36.
Wong H, Lam H, Fong A, Leung S, Chin T, Lo C, et al. Frequency and distribution of chest radiographic findings in patients positive for COVID-19. Radiology. 2020;72–8.
37.
Fang Y, Zhang H, Xie J, Lin M, Ying L, Pang P, et al. Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR. Radiology. 2020;115–7.
38.
Baj J, Karakuła-Juchnowicz H, Teresiński G, Buszewicz G, Ciesielka M, Sitarz E, et al. COVID-19: Specific and non-specific clinical manifestations and symptoms: The Current State of Knowledge. J Clin Med. 2020;1753.
39.
Bramson R, Griscom N, Cleveland R. Interpretation of chest radiographs in infants with cough and fever. Radiology. 2005;22–9.
40.
Carfì A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;603–5.
41.
Zeng Y, Fu J, Yu X, Huang Z, Yin X, Geng D, et al. Should computed tomography (CT) be used as a screening or follow-up tool for asymptomatic patients with SARS-CoV-2 infection? Quant Imaging Med Surg. 2020;1150–2.
42.
Kim H, Capaccione K, Li G, Luk L, Widemon R, Rahman O, et al. The role of initial chest X-ray in triaging patients with suspected COVID-19 during the pandemic. Emerg Radiol. 2020;617–62.
43.
Borghesi A, Zigliani A, Masciullo R, Golemi S, Maculotti P, Farina D, et al. Radiographic severity index in COVID-19 pneumonia: relationship to age and sex in 783 Italian patients. Radiol Med. 2020;461–4.
44.
Wallace W, Fitch P, Simpson J, Howie S. Inflammation associated remodelling and fibrosis in the lung: a process and an end point. Int J Exp Pathol. 2007;103–10.
45.
Strieter R. Pathogenesis and natural history of usual interstitial pneumonia: the whole story or the last chapter of a long novel. Chest. 2005;526S – 532.
46.
Sonnweber T, Sahanic S, Pizzini A, Luger A, Schwabl C, Sonnweber B, et al. Cardiopulmonary recovery after COVID-19 -an observational prospective multi-center trial. Eur Respir J. 2020;
47.
Cool C, Groshong S, Rai P, Henson P, Scott S, Brown K. Fibroblast foci are not discrete sites of lung injury or repair: the fibroblast reticulum. Am J Respir Crit Care Med. 2006;654–8.
48.
Venkataraman T, Frieman M. The role of epidermal growth factor receptor (EGFR) signaling in SARS coronavirus-induced pulmonary fibrosis. Antiviral Res. 2017;142–50.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
